Navidea Biopharmaceuticals, Inc.
NAVBQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.01K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $10,008.00 |
|---|---|
| Enterprise Value | $-1,795,051.00 |
| Earnings per Share | $-0.59 |
| Beta | -4.82 |
| Outstanding Shares | 99,364,154 |
Return
| Return on Equity | 15.27% |
|---|---|
| Return on Assets | -8.77% |
| Return on Invested Capital | 463.27% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | -2942.71 |
| Enterprise Value to EBIT | 0.17 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | -1.15 |
| Debt to Equity | -0.63 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.08
Consensus analyst estimateRevenue Estimate
$600,000
Consensus analyst estimateNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-0.08
Consensus analyst estimateRevenue Estimate
$600,000
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Navidea Biopharmaceuticals Inc
11 employees
CEO: Jed Latkin
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm dedicated to advancing and commercializing specialized agents for immunodiagnosis and innovative immunotherapeutics. The company operates across two distinct segments: Diagnost...